Gilead pledges $100m to address AIDS in ten-year commitment

Promising data for ViiV’s two-drug HIV regimen
Credit: Jarun Ontakrai

Gilead Sciences has launched a ten-year, $100 million commitment to address the HIV/AIDS epidemic in the Southern United States.

As part of this commitment, the company will partner with three coordinating centres to lead the corporate giving program of the initiative: Emory University Rollins School of Public Health, the University of Houston Graduate College of Social Work and the Southern AIDS Coalition.

These centres will identify and provide funding to local organisations that are committed to addressing the epidemic throughout the region, focusing on capacity building and shared knowledge; wellbeing, mental health and trauma-informed care; and awareness, education and anti-stigma campaigns.

Gregg Alton, Executive Vice President, Corporate and Medical Affairs, Gilead Sciences, said: “We recognise a collaborative effort is needed and we are very pleased to partner with local organizations that are uniquely positioned to address the epidemic on the ground.”

Nearly half of all people dying from HIV/AIDS in the United States live in a Southern state.

According to the Centres for Disease Control and Prevention (CDC), the Southern United States accounts for approximately 45% of all people living with an HIV diagnosis in the country, despite being home to only one third of the population.